Sanofi-Aventis U.S. Llc
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2004-08-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofi-aventis.us
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
36
Drug Approvals
Dronedarone Hydrochloride Tablets
- Product Name
- 盐酸决奈达隆片
- Approval Number
- 国药准字HJ20210084
- Approval Date
- Dec 20, 2021
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
News
Q32 Bio Names Adrien Sipos as Interim CMO to Lead Alopecia Areata Drug Development
Q32 Bio appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer to oversee the ongoing SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata treatment.
Major Insulin Manufacturers Agree to $35 Monthly Price Caps in State Settlements
Sanofi and Novo Nordisk have reached settlements with Maine and Minnesota attorneys general to cap insulin prices at $35 per month through 2029.
Propionic Acid Supplementation Shows Promise in Multiple Sclerosis Treatment
Propionic acid, a short-chain fatty acid produced by gut bacteria, may play a beneficial role in multiple sclerosis (MS) pathology by influencing immune and nervous systems.
Advancements in Clinical Trials for Fabry Disease, C. difficile Infections, and Mydriasis
• Clinical trials are actively progressing for Fabry Disease, with companies like Idorsia and Sanofi Genzyme developing novel therapies. • Emerging treatments like Venglustat and Pegunigalsidase alfa are expected to significantly impact the Fabry Disease market in the coming years. • Research and development efforts are also focused on Clostridium Difficile Infections, with Vedanta Biosciences leading Phase 3 trials for VE303. • Mydriasis treatments are advancing, with companies like Eyenovia exploring solutions like MYDCOMBI for pupil dilation.
EU Approves Sanofi's Cablivi as First Targeted Therapy for Rare Blood Clotting Disorder aTTP
The European Commission has authorized Cablivi (caplacizumab) as the first specific treatment for acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting disorder.